Non al co holic fatty liver dis ease (NAFLD) is di agnosed in a sig nifi cant pro por tion of coro nary ar tery dis ease and type 2 dia be tes pa tients, ex ac er bat ing the un der ly ing dis ease. It is fre quently as so ci ated with abdomi nal obesity, dia be tes mel li tus, ar te rial hy per ten sion, age over 45 years and the ra tio of trans ami nase ac tiv ity [10, 6] . Although this dis ease of ten comes across as ymp to matic, the pro gres sion of stea to sis to stea to he pa ti tis is found in almost half of cases and in not less than 1/6 of pa tients fi bro sis of liver de vel ops. It is also known that 72% of patients with coro nary heart dis ease com bined with type 2 dia be tes are di ag nosed with NAFLD [3, 4, 6] The prob lem of the de vel op ment and pro gres sion of NAFLD in ad di tion to coro nary heart dis ease and type 2 dia be tes mel li tus is one of the most im por tant and ur gent tasks of in ter nal medi cine, since it leads to the wors en ing of comor bid dis eases [1] .
ing [6, 10] . The de fini tive di ag no sis of NAFLD is based on liver bi op sies, which show in flam ma tory in fil trates, Mal lory bod ies and signs of fi bro sis [5, 7, 2] . Al though liver bi opsy is the cur rent gold stan dard for di ag no sis of NAFLD, it is not a prac ti cal screen ing tool given the cost, time-consuming na ture and po ten tial mor bid ity of this pro ce dure [2, 3, 10] .
How ever, more at ten tion is paid to early di ag no sis of NAFLD by us ing ei ther spe cial sets of de signed for mu las with bio chemi cal pa rame ters, data Fi broscan, or res pi ratory tests with 13C-meth acethine (C13-MBT) and 13C-amino pyrine [3, 5, 7] .
The aim of the study was to examine the liver detoxification function by comparing a 13C-methacethine breath test, with a Forns formula and with liver transaminases in patients with coronary heart disease and type 2 diabetes mellitus in combination with nonalcoholic fatty disease.
MATERIAL AND METHODS
The study in volved 52 pa tients with type 2 dia be tes (male 48, fe male 83, aged 43 to 82 years, mean age 60.94 ± 0.82 years). Among them, 32 pa tients with type 2 dia betes (mean age 64.5 ± 1.58) and 20 pa tients with coro nary ar tery dis ease, sta ble an gina and II FC (mean age 54.60 ± 2.74).
Bio chemi cal tests were taken for the pres ence of the func tional state of liver dis or ders, in clud ing to tal bili rubin, AST, ALT, AST/SLT and lipi do gram.
Stud ies for the pres ence of fi brotic changes were conducted by cal cu lat ing a Forns for mula: 7.811-3.131 ln (plate lets) + 0.781 ln (GGTP) +3.467 ln (age) -0.014 (cho les terol, mg/dl). Re sult less than 4.2 cor re sponded to ab sence of fi bro sis.
To de ter mine the de gree of liver in jury all pati ents under went a 13C-MBT. These an ti toxic func tion were evaluated on the ba sis of the total con cen tra tion of 13CO2, 40 and 120 min utes [5] .
RESULTS
Ac cord ing to the ul tra sonogra phy of pa tients with coro nary ar tery dis ease and type 2 dia be tes there was a dif fuse in crease in the echo gen ic ity of the liver pa renchyma a slight in crease in its size, which is con sis tent with stea to sis: liver echo gen ic ity was sig nifi cantly higher than the echo gen ic ity of a nor mal kid ney or psoas. In other patients hy pere cho genic liver pa ren chyma and a slight en large ment of the por tal vein (more than 13 mm in diame ter), was ob served which is more typi cal of stea tohepa ti tis. For the group of fi bro sis pa tients these items were char ac ter is tic: some rough in ner echostruc ture, peri por tal fi bro sis, echo genic mem brane le sions (fi brotic trans forma tion of branches of portal ves sels, echo genic strips) and signs of por tal hy per ten sion. Groups were formed based on the ul tra sound in for ma tion, which showed their clinical NAFLD stage. Among them, 10 pa tients were found with stea to sis, 12 -with stea to he pa ti tis, 5 -with fi bro sis and in 5 pa tients NAFLD was not found.
Com pari son of bio chemi cal pa rame ters in pa tients with type 2 dia be tes in com bi na tion with coro nary ar tery dis ease, found that lev els of biliru bin, AST, ALT and AST/ALT were sig nifi cantly dif fer ent from that of patients with out NAFLD (p<0.05).
The dif fer ence be tween TG was un re li able in the fi brosis group (p<0.05) and a group with out NAFLD (p<0.01). How ever, as in pre vi ous re sults, in di ca tor lipi do gram did not ex ceed nor mal limits, de spite the pres ence of NAFLD.
Use of a Forns for mula re vealed in subgroups of clini cal forms of NAFLD func tional and mor pho logi cal changes in the liver. This for mula clearly in di cated the ab sence of fibro sis in groups of stea to sis, stea to he pa ti tis and fi bro sis (<4.25), and clearly showed its pres ence at a value 5.26 in pa tients with fi brotic changes. The re li abil ity of the dif ference was be tween groups of pa tients with stea to he pa ti tis and fi bro sis (p<0.05), be tween groups stea to he pa ti tis and group of liver with out NAFLD (p<0.05). A strong negative re la tion ship was marked be tween the Forns for mula and ALT lev els (r = -0.944) and bili ru bin (r = -0.967) in pa tients with fi bro sis.
As a re sult of 13C-MBT, pa tients with out NAFLD indexed an ti toxic liver func tion be yond the norm (20.44 ± 0.66%). Patients with stea to sis from stea to he pa ti tis showed a mod er ate re duc tion in liver func tion, re spectively, (10.94±1.22%) and (11.69±0.48%). A sig nifi cant differ ence be tween the rates of two sub groups were found, while fi bro sis was al most three times lower than other in di ca tors and meant a marked re duc tion in the an titoxic func tion of the liver (6.32±1.47%).
Ana lyse of liver trans ami nases and data-13C methacetine tests showed a higher meta bolic rate cor re lated with higher cu mu la tive doses 40 and 120 min utes and nor mal ALT lev els (p<0.05).
A re duc tion in the rate of me tabo lism and cu mu la tive doses 40 and 120 min utes was ob served with in creas ing lev els of ALT (p<0.05).
Com pari sons of the rates of me tabo lism (p<0.01) between cu mu la tive dose at 40 min utes (p<0.01) with those at 120 min utes (p<0.01), in two groups of pa tients displayed more sighs of stea to he pa ti tis than signs of stea to sis.
DISCUSSION
1. When moni tor ing the he patic func tion in pa tients with coro nary ar tery dis ease and type 2 dia be tes it is de sirable to in clude data from the ul tra sound of the liver ex ami na tion of he patic trans ami nases and the evaluation a 13C-meth acetin test which shows the meta bolic rate and the cu mu la tive dose per cent. This data re flects de via tions in the functional state and the ini tial manifes ta tions of fi brotic changes in the liver pa ren chyma. 2. The re sult of the Forns for mula cal cu la tion must be more than 4.25 to di ag nose the fi bro sis as clini cal stage NAFLD. 3. Use of the 13C-methacet ine test to di ag nose patho logical changes in the liver in the early stages of NAFLD (stea to sis, stea to he pa ti tis) is posi tively cor re lated with the Forns for mula. 4. It is likely to find fi bro sis of the liver when Forns formula is over 4.25, 13C-breath test at least 10%, lower lev els of ALT and bili ru bin, and ele vated tri glyc erides contrary.
